Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

621. Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder Full Text available with Trip Pro

Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder Article Text Aetiology Atypical

2012 Evidence-Based Mental Health

622. Mortality risk in people with schizophrenia may vary according to class of antipsychotic used and concomitant medication

Mortality risk in people with schizophrenia may vary according to class of antipsychotic used and concomitant medication Mortality risk in people with schizophrenia may vary according to class of antipsychotic used and concomitant medication | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Mortality risk in people with schizophrenia may vary according to class of antipsychotic used and concomitant medication Article Text Aetiology

2012 Evidence-Based Mental Health

623. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States

Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment (...) of schizophrenia in the United States Ascher-Svanum H, Furiak NM, Lawson AH, Klein TM, Smolen LJ, Conley RR, Culler SD Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study assessed cost-effectiveness of standard oral tablets compared

2012 NHS Economic Evaluation Database.

624. Cost-effectiveness of sertindole among atypical antipsychotics in the treatment of schizophrenia in South Korea Full Text available with Trip Pro

Cost-effectiveness of sertindole among atypical antipsychotics in the treatment of schizophrenia in South Korea Cost-effectiveness of sertindole among atypical antipsychotics in the treatment of schizophrenia in South Korea Cost-effectiveness of sertindole among atypical antipsychotics in the treatment of schizophrenia in South Korea Kim BR, Lee TJ, Lee HJ, Park BH, Yang BM Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to explore the cost-effectiveness of sertindole, compared with risperidone, olanzapine, and quetiapine, for the treatment of patients with schizophrenia, in South Korea. The authors concluded that sertindole could be considered for patients who had failed to respond to other atypical antipsychotic

2012 NHS Economic Evaluation Database.

625. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

626. In Ethiopia, people with schizophrenia are at higher risk of 5-year mortality than the general population

In Ethiopia, people with schizophrenia are at higher risk of 5-year mortality than the general population In Ethiopia, people with schizophrenia are at higher risk of 5-year mortality than the general population | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In Ethiopia, people with schizophrenia are at higher risk of 5-year mortality than the general population Article Text Prognosis In Ethiopia, people with schizophrenia

2012 Evidence-Based Mental Health

627. Review: premorbid IQ is inversely associated with future risk of schizophrenia

Review: premorbid IQ is inversely associated with future risk of schizophrenia Review: premorbid IQ is inversely associated with future risk of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: premorbid IQ is inversely associated with future risk of schizophrenia Article Text Aetiology Review: premorbid IQ is inversely associated with future risk of schizophrenia Statistics from Altmetric.com Question Question

2012 Evidence-Based Mental Health

628. Mortality gap between people with schizophrenia or bipolar disorder and the general population persists in England

Mortality gap between people with schizophrenia or bipolar disorder and the general population persists in England Mortality gap between people with schizophrenia or bipolar disorder and the general population persists in England | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Mortality gap between people with schizophrenia or bipolar disorder and the general population persists in England Article Text Prognosis Mortality gap between people

2012 Evidence-Based Mental Health

629. Only 10% of people with schizophrenia show sustained improvements over 3 years Full Text available with Trip Pro

Only 10% of people with schizophrenia show sustained improvements over 3 years Only 10% of people with schizophrenia show sustained improvements over 3 years | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Only 10% of people with schizophrenia show sustained improvements over 3 years Article Text Prognosis Only 10% of people with schizophrenia show sustained improvements over 3 years Free Wolfgang Gaebel , Mathias Riesbeck Statistics from

2012 Evidence-Based Mental Health

630. Predicting the development of schizophrenia in high-risk populations: systematic review of the predictive validity of prodromal criteria Full Text available with Trip Pro

Predicting the development of schizophrenia in high-risk populations: systematic review of the predictive validity of prodromal criteria There is a great deal of debate on the usefulness and accuracy of prodromal criteria in predicting schizophrenia. The risk of treating people who screen false positive with medication is considerable. Yet intervening during the prodromal stage of illness may reduce the burden caused by schizophrenia.To draw together the evidence base for the predictive (...) -0.70) respectively and for basic-symptoms criteria sensitivity and specificity was 0.97 (95% CI 0.91-1.00) and 0.59 (95% CI 0.48-0.70) respectively.Both ultra-high-risk criteria and basic-symptoms criteria are useful in predicting the development of schizophrenia among high-risk populations.

2012 EvidenceUpdates

631. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. (Abstract)

Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Relapse prevention with antipsychotic drugs compared with placebo in patients with schizophrenia has not been sufficiently addressed by previous systematic reviews. We aimed to assess the association between such drugs and various outcomes in patients with schizophrenia to resolve controversial issues.We searched the Cochrane Schizophrenia Group's specialised register for reports (...) published before Nov 11, 2008; and PubMed, Embase, and ClinicalTrials.gov for those before June 8, 2011. We also contacted pharmaceutical companies and searched the reference lists of included studies and previous reviews. Randomised trials of patients with schizophrenia continued on or withdrawn from any antipsychotic drug regimen after stabilisation were eligible. Our primary outcome was relapse between 7 and 12 months. We also examined safety and various functional outcomes. We used the random

2012 Lancet

632. Group art therapy as an adjunctive treatment for people with schizophrenia: multicentre pragmatic randomised trial. Full Text available with Trip Pro

Group art therapy as an adjunctive treatment for people with schizophrenia: multicentre pragmatic randomised trial. To evaluate the clinical effectiveness of group art therapy for people with schizophrenia and to test whether any benefits exceed those of an active control treatment.Three arm, rater blinded, pragmatic, randomised controlled trial.Secondary care services across 15 sites in the United Kingdom.417 people aged 18 or over, who had a diagnosis of schizophrenia and provided written (...) or 24 months.Referring people with established schizophrenia to group art therapy as delivered in this trial did not improve global functioning, mental health, or other health related outcomes.Current Controlled Trials ISRCTN46150447.

2012 BMJ Controlled trial quality: predicted high

633. Lack of association between the G-660C polymorphism in the dopamine transporter gene (SLC6A3) and schizophrenia in the Iranian population Full Text available with Trip Pro

Lack of association between the G-660C polymorphism in the dopamine transporter gene (SLC6A3) and schizophrenia in the Iranian population Dopaminergenic system plays an essential role in the plasticity of the human brain. The dopamine transporter gene (SLC6A3) mediates active reuptake of dopamine from synapsis, terminates dopamine signals, and therefore, is implicated in a number of dopamine-related disorders like psychosis. Variations in the form of single nucleotide polymorphisms in the core (...) promoter of the SLC6A3 gene are reported to be involved in the pathogenesis of schizophrenia. In this study, we also attempted to establish the possible role of the polymorphism G-660C in the SLC6A3 gene promoter in schizophrenia in a case-control study.The allele and genotype frequency were analyzed in an Iranian cohort of 200 unrelated patients and 200 controls using polymerase chain reaction and restriction fragment length polymorphism.The genotype frequency for case and control groups was GG 100

2012 Indian journal of human genetics

634. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. Full Text available with Trip Pro

Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. To investigate whether the mortality gap has reduced in recent years between people with schizophrenia or bipolar disorder and the general population.Record linkage study.English hospital episode statistics and death registration data for patients discharged 1999-2006.People discharged from inpatient care with a diagnosis (...) of schizophrenia or bipolar disorder, followed for a year after discharge.Age standardised mortality ratios at each time, comparing the mortality in people with schizophrenia or bipolar disorder with mortality in the general population. Poisson test of trend was used to investigate trend in ratios over time.By 2006 standardised mortality ratios in the psychiatric cohorts were about double the population average. The mortality gap widened over time. For people discharged with schizophrenia, the ratio was 1.6

2011 BMJ

635. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model

Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision (...) with schizophrenia who had been non-adherent or partially adherent with oral antipsychotics. Interventions The study compared olanzapine LAI to oral olanzapine, risperidone-LAI, paliperidone-LAI and haloperidol-LAI. Location/setting USA/out-patient secondary care. Methods Analytical approach: A fixed-time advanced Monte Carlo microsimulation with quarterly cycles was used to assess the cost-effectiveness of the interventions under study. The authors reported that the model was developed in consultation

2011 NHS Economic Evaluation Database.

636. Aripiprazole effective for schizophrenia and well tolerated

Aripiprazole effective for schizophrenia and well tolerated PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Aripiprazole effective for schizophrenia and well tolerated Clinical question How effective is aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses? Bottom line On the basis of very limited data, aripiprazole (...) rate of 38.5% was considerable, clearly limiting the validity of the results. Long term data (longer than 26 weeks) are not available. All of the four included studies were sponsored by the manufacturer of aripiprazole. Context Schizophrenia is usually a chronic and disabling psychiatric disorder, which affects approximately 1 per cent of the population worldwide, with little gender difference. In many countries of the industrialised world, second generation (atypical) antipsychotics have become

2011 Cochrane PEARLS

637. Aripiprazole - Schizophrenia and Related Psychotic Disorders

Aripiprazole - Schizophrenia and Related Psychotic Disorders Common Drug Review CEDAC Meeting – June 15, 2011 Notice of CEDAC Final Recommendation – July 18, 2011 Page 1 of 3 © 2011 CADTH CEDAC FINAL RECOMMENDATION ARIPIPRAZOLE – REQUEST FOR ADVICE (Abilify – Bristol-Myers Squibb Canada) Indication: Schizophrenia and Related Psychotic Disorders Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that aripiprazole be listed for the treatment of schizophrenia (...) of schizophrenia and related psychotic disorders, which is the focus of this recommendation. Aripiprazole also has a Health Canada indication for the acute treatment of manic or mixed episodes in bipolar I disorder. It has partial agonist activity at the dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at the serotonin 5-HT2A receptors. The Health Canada-recommended starting dose for aripiprazole is 10 mg to 15 mg once a day, with a maximum daily dose of 30 mg. It is available as 2 mg, 5 mg

2011 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

638. Amisulpride for adults with refractory schizophrenia: a review of the clinical effectiveness and safety

Amisulpride for adults with refractory schizophrenia: a review of the clinical effectiveness and safety Amisulpride for adults with refractory schizophrenia: a review of the clinical effectiveness and safety Amisulpride for adults with refractory schizophrenia: a review of the clinical effectiveness and safety Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Amisulpride for adults with refractory schizophrenia: a review of the clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions Results from one non-randomized study suggest that the odds of remission, recovery or adequate quality of life with both amisulpride and clozapine were not statistically different

2011 Health Technology Assessment (HTA) Database.

639. Effects of progressive muscle relaxation on state anxiety and subjective well-being in people with schizophrenia: a randomized controlled trial (Abstract)

Effects of progressive muscle relaxation on state anxiety and subjective well-being in people with schizophrenia: a randomized controlled trial To examine the efficacy of a single progressive muscle relaxation session compared with a control condition on state anxiety, psychological stress, fatigue and subjective well-being in patients with schizophrenia.Randomized controlled trial.An acute inpatient care unit of an University Psychiatric Centre.Sixty-four out of 88 eligible patients (...) subjective well-being. Between-group differences in post scores were found for state anxiety, subjective well-being and psychological stress, but not for fatigue. The effect size favouring progressive muscle relaxation was 1.26 for subjective well-being and -1.25 and -1.02 for respectively state anxiety and psychological stress.Progressive muscle relaxation is highly effective in reducing acute feelings of stress and anxiety in patients with schizophrenia. A reduction in stress and state anxiety

2011 EvidenceUpdates Controlled trial quality: uncertain

640. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Full Text available with Trip Pro

A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Cognitive remediation therapy for schizophrenia was developed to treat cognitive problems that affect functioning, but the treatment effects may depend on the type of trial methodology adopted. The present meta-analysis will determine the effects of treatment and whether study method or potential moderators influence the estimates.Electronic databases were searched up to June 2009 using variants of the key (...) words "cognitive," "training," "remediation," "clinical trial," and "schizophrenia." Key researchers were contacted to ensure that all studies meeting the criteria were included. This produced 109 reports of 40 studies in which ≥70% of participants had a diagnosis of schizophrenia, all of whom received standard care. There was a comparison group and allocation procedure in these studies. Data were available to calculate effect sizes on cognition and/or functioning. Data were independently extracted

2011 EvidenceUpdates